Targeted Imaging MPI technology aligns with hospitals and research centers seeking advanced functional imaging to monitor real-time biological events, offering a differentiator for sales conversations with early adopters in translational research and oncology.

Key References Notable customers like City of Hope and recent seed/Series B funding milestones signal strong validation and potential for expansion with academic medical centers and translational research institutes.

Funding Momentum Significant funding rounds and investor backing suggest a favorable market signal; leverage funding timelines to align procurement cycles and pilot opportunities with prospective high-value accounts.

Portfolio Synergy MPI offers unique biomarker targeting and vascular tracing capabilities that complement existing imaging fleets, presenting upsell and integration opportunities for institutions already using CT, MRI, PET/SPECT.

Small Team, Customization With a small team and specialized product momentum, prioritize high-touch, consultative selling, pilot programs, and rapid on-site demonstrations to accelerate adoption in research labs and clinical pilots.